269 related articles for article (PubMed ID: 30526029)
1. Non-Whole-Gland High-Intensity Focused Ultrasound vs Whole-Gland High-Intensity Focused Ultrasound for Management of Localized Prostate Cancer: 1-Year Oncological and Functional Outcomes.
Lei Y; Zanker P; Yildiz S; Hancke K; Seidl D; Koch O; Schwentner C; Mundhenk J
J Endourol; 2019 Feb; 33(2):100-106. PubMed ID: 30526029
[TBL] [Abstract][Full Text] [Related]
2. Comparisons of Oncological and Functional Outcomes Between Primary Whole-Gland Cryoablation and High-Intensity Focused Ultrasound for Localized Prostate Cancer.
Liu YY; Chiang PH
Ann Surg Oncol; 2016 Jan; 23(1):328-34. PubMed ID: 26088651
[TBL] [Abstract][Full Text] [Related]
3. High-intensity Focused Ultrasound (HIFU) as salvage therapy for radio-recurrent prostate cancer: predictors of disease response.
Dason S; Wong NC; Allard CB; Hoogenes J; Orovan W; Shayegan B
Int Braz J Urol; 2018; 44(2):248-257. PubMed ID: 29211405
[TBL] [Abstract][Full Text] [Related]
4. Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients.
Crouzet S; Chapelon JY; Rouvière O; Mege-Lechevallier F; Colombel M; Tonoli-Catez H; Martin X; Gelet A
Eur Urol; 2014 May; 65(5):907-14. PubMed ID: 23669165
[TBL] [Abstract][Full Text] [Related]
5. Hemi salvage high-intensity focused ultrasound (HIFU) in unilateral radiorecurrent prostate cancer: a prospective two-centre study.
Baco E; Gelet A; Crouzet S; Rud E; Rouvière O; Tonoli-Catez H; Berge V; Chapelon JY; Eggesbø HB
BJU Int; 2014 Oct; 114(4):532-40. PubMed ID: 24930692
[TBL] [Abstract][Full Text] [Related]
6. Medium-term Outcomes after Whole-gland High-intensity Focused Ultrasound for the Treatment of Nonmetastatic Prostate Cancer from a Multicentre Registry Cohort.
Dickinson L; Arya M; Afzal N; Cathcart P; Charman SC; Cornaby A; Hindley RG; Lewi H; McCartan N; Moore CM; Nathan S; Ogden C; Persad R; van der Meulen J; Weir S; Emberton M; Ahmed HU
Eur Urol; 2016 Oct; 70(4):668-674. PubMed ID: 26951947
[TBL] [Abstract][Full Text] [Related]
7. Whole-gland salvage high-intensity focused ultrasound therapy for localized prostate cancer recurrence after external beam radiation therapy.
Uddin Ahmed H; Cathcart P; Chalasani V; Williams A; McCartan N; Freeman A; Kirkham A; Allen C; Chin J; Emberton M
Cancer; 2012 Jun; 118(12):3071-8. PubMed ID: 22071795
[TBL] [Abstract][Full Text] [Related]
8. [High-intensity focussed ultrasound in low-risk prostate cancer - oncological outcome and postinterventional quality of life of an inexperienced therapy centre in comparison with an experienced therapy centre].
Baumunk D; Andersen C; Heile U; Ebbing J; Cash H; Porsch M; Liehr UB; Janitzky A; Wendler JJ; Schindele D; Blaschke S; Miller K; Schostak M
Aktuelle Urol; 2013 Jul; 44(4):285-92. PubMed ID: 23888408
[TBL] [Abstract][Full Text] [Related]
9. High-intensity focused ultrasound for the treatment of prostate cancer: A prospective trial with long-term follow-up.
Mearini L; D'Urso L; Collura D; Nunzi E; Muto G; Porena M
Scand J Urol; 2015; 49(4):267-74. PubMed ID: 25485722
[TBL] [Abstract][Full Text] [Related]
10. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study.
Ahmed HU; Hindley RG; Dickinson L; Freeman A; Kirkham AP; Sahu M; Scott R; Allen C; Van der Meulen J; Emberton M
Lancet Oncol; 2012 Jun; 13(6):622-32. PubMed ID: 22512844
[TBL] [Abstract][Full Text] [Related]
11. Can pre- and postoperative magnetic resonance imaging predict recurrence-free survival after whole-gland high-intensity focused ablation for prostate cancer?
Rosset R; Bratan F; Crouzet S; Tonoli-Catez H; Mège-Lechevallier F; Gelet A; Rouvière O
Eur Radiol; 2017 Apr; 27(4):1768-1775. PubMed ID: 27436018
[TBL] [Abstract][Full Text] [Related]
12. Salvage external beam radiotherapy for recurrent prostate adenocarcinoma after high-intensity focused ultrasound as primary treatment.
Munoz F; Guarneri A; Botticella A; Gabriele P; Moretto F; Panaia R; Ruggieri A; D'Urso L; Muto G; Filippi AR; Ragona R; Ricardi U
Urol Int; 2013; 90(3):288-93. PubMed ID: 23364287
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of post-ablation mpMRI as a predictor of residual prostate cancer after focal high intensity focused ultrasound (HIFU) ablation.
Khandwala YS; Morisetty S; Ghanouni P; Fan RE; Soerensen SJC; Rusu M; Sonn GA
Urol Oncol; 2022 Nov; 40(11):489.e9-489.e17. PubMed ID: 36058811
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) procedure in men with primary localized, non-metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry.
Lovegrove CE; Peters M; Guillaumier S; Arya M; Afzal N; Dudderidge T; Hosking-Jervis F; Hindley RG; Lewi H; McCartan N; Moore CM; Nigam R; Ogden C; Persad R; Virdi J; Winkler M; Emberton M; Ahmed HU; Shah TT; Minhas S
BJU Int; 2020 Jun; 125(6):853-860. PubMed ID: 31971335
[TBL] [Abstract][Full Text] [Related]
15. Role of Systematic Control Biopsies following Partial Gland Ablation with High-Intensity Focused Ultrasound for Clinically Significant Prostate Cancer.
Rompré-Brodeur A; Marcq G; Tholomier C; Fugaru I; Loutochin O; Anidjar M; Bladou F
J Urol; 2021 Nov; 206(5):1177-1183. PubMed ID: 34251879
[TBL] [Abstract][Full Text] [Related]
16. Primary whole-gland ablation for localized prostate cancer with high-intensity focused ultrasound: The important predictors of biochemical recurrence.
Chen PY; Chiang PH; Liu YY; Chuang YC; Cheng YT
Int J Urol; 2018 Jun; 25(6):615-620. PubMed ID: 29756298
[TBL] [Abstract][Full Text] [Related]
17. Salvage partial gland ablation for recurrent prostate cancer following primary partial gland ablation: Functional and oncological outcomes.
Qaoud Y; Herrera-Caceres JO; Bass R; Berjaoui MB; Tiwari R; Kenk M; Lajkosz K; Finelli A; Perlis N; Klotz L; Fleshner N
Urol Oncol; 2022 Jul; 40(7):343.e1-343.e6. PubMed ID: 35537905
[TBL] [Abstract][Full Text] [Related]
18. Salvage Hemiablation High Intensity Focused Ultrasound for unilateral radio-recurrent prostate cancer.
Aoun F; Albisinni S; Biaou I; Peltier A; Limani K; Roumeguère T; van Velthoven R
Prog Urol; 2019 Oct; 29(12):627-633. PubMed ID: 31400963
[TBL] [Abstract][Full Text] [Related]
19. Urethra-sparing high-intensity focused ultrasound for localized prostate cancer: Functional and oncological outcomes.
Shoji S; Nakano M; Fujikawa H; Endo K; Hashimoto A; Tomonaga T; Terachi T; Uchida T
Int J Urol; 2015 Nov; 22(11):1043-9. PubMed ID: 26251127
[TBL] [Abstract][Full Text] [Related]
20. Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement.
Deivasigamani S; Kotamarti S; Rastinehad AR; Salas RS; de la Rosette JJMCH; Lepor H; Pinto P; Ahmed HU; Gill I; Klotz L; Taneja SS; Emberton M; Lawrentschuk N; Wysock J; Feller JF; Crouzet S; Kumar M P; Seguier D; Adams ES; Michael Z; Abreu A; Jack Tay K; Ward JF; Shinohara K; Katz AE; Villers A; Chin JL; Stricker PD; Baco E; Macek P; Ahmad AE; Chiu PKF; Crawford ED; Rogers CG; Futterer JJ; Rais-Bahrami S; Robertson CN; Hadaschik B; Marra G; Valerio M; Chong KT; Kasivisvanathan V; Tan WP; Lomas D; Walz J; Guimaraes GC; Mertziotis NI; Becher E; Finelli A; Kasraeian A; Lebastchi AH; Vora A; Rosen MA; Bakir B; Arcot R; Yee S; Netsch C; Meng X; de Reijke TM; Tan YG; Regusci S; Benjamin TGR; Olivares R; Noureldin M; Bianco FJ; Sivaraman A; Kim FJ; Given RW; Dason S; Sheetz TJ; Shoji S; Schulman A; Royce P; Shah TT; Scionti S; Salomon G; Laguna P; Tourinho-Barbosa R; Aminsharifi A; Cathelineau X; Gontero P; Stabile A; Grummet J; Ledbetter L; Graton M; Stephen Jones J; Polascik TJ;
Eur Urol; 2023 Dec; 84(6):547-560. PubMed ID: 37419773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
